Promise and failure of targeted therapy in breast cancer

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 1, 2012, Pages 356-374

  Giordano, Antonio ^a   Tagliabue, Elda ^b   Pupa, Serenella M ^b  

^a TEMPLE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Molecular profiling; Review; Targeted therapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; GEFITINIB; GEMCITABINE; LAPATINIB; LETROZOLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; GENE AMPLIFICATION; HUMAN; OVERALL SURVIVAL; TREATMENT FAILURE; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84862637116     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/273     Document Type: Article

References (179)

1. O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo: Advances in breast cancer: pathways to personalized medicine. Clin.Cancer Res. 14, 7988-7999 (2008)
2. S. Di Cosimo and J. Baselga: Management of breast cancer with targeted agents: importance of heterogenicity. Nat.Rev.Clin Oncol. 7, 139-147 (2010)
3. D. Hanahan and R. A. Weinberg: The hallmarks of cancer. Cell 100, 57-70 (2000)
4. C. M. Perou, T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale, P. O. Brown, and D. Botstein: Molecular portraits of human breast tumours. Nature 406, 747-752 (2000)
5. T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, L. P. Eystein, and A. L. Borresen-Dale: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc.Natl.Acad.Sci U.S.A. 98, 10869-10874 (2001)
6. H. Mouridsen, A. Giobbie-Hurder, A. Goldhirsch, B. Thurlimann, R. Paridaens, I. Smith, L. Mauriac, J. F. Forbes, K. N. Price, M. M. Regan, R. D. Gelber, and A. S. Coates: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N.Engl.J Med. 361, 766-776 (2009)
7. V. C. Jordan: Tamoxifen: a most unlikely pioneering medicine. Nat.Rev.Drug Discov. 2, 205-213 (2003)
8. M. P. Cole, C. T. Jones, and I. D. Todd: A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br.J Cancer. 25, 270-275 (1971)
9. M. Baum, D. M. Brinkley, J. A. Dossett, K. McPherson, J. S. Patterson, R. D. Rubens, F. G. Smiddy, B. A. Stoll, A. Wilson, J. C. Lea, D. Richards, and S. H. Ellis: Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 2, 450 (1983)
10. B. J. Furr and V. C. Jordan: The pharmacology and clinical uses of tamoxifen. Pharmacol.Ther. 25, 127-205 (1984)
11. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467 (1998)
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687- 1717 (2005)
13. Z. Desta, B. A. Ward, N. V. Soukhova, and D. A. Flockhart: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol.Exp Ther. 310, 1062-1075 (2004)
14. D. Y. Wang, R. Fulthorpe, S. N. Liss, and E. A. Edwards: Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol. 18, 402-411 (2004)
15. J. D. Chen and R. M. Evans: A transcriptional corepressor that interacts with nuclear hormone receptors. Nature. 377, 454-457 (1995)
16. A. J. Horlein, A. M. Naar, T. Heinzel, J. Torchia, B. Gloss, R. Kurokawa, A. Ryan, Y. Kamei, M. Soderstrom, C. K. Glass, and M. G. Rosenfeld.: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 377, 397-404 (1995)
17. P. J. Kushner, D. A. Agard, G. L. Greene, T. S. Scanlan, A. K. Shiau, R. M. Uht, and P. Webb: Estrogen receptor pathways to AP-1. J.Steroid Biochem.Mol.Biol. 74, 311-317 (2000)
18. R. M. Lavinsky, K. Jepsen, T. Heinzel, J. Torchia, T. M. Mullen, R. Schiff, A. L. Del Rio, M. Ricote, S. Ngo, J. Gemsch, S. G. Hilsenbeck, C. K. Osborne, C. K. Glass, M. G. Rosenfeld, and D. W. Rose: Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc.Natl.Acad.Sci.U.S.A 95, 2920- 2925 (1998)
19. R. Schiff, S. Massarweh, J. Shou, and C. K. Osborne: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 9, 447S-454S (2003)
20. J. D. Graham, D. L. Bain, J. K. Richer, T. A. Jackson, L. Tung, and K. B. Horwitz: Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids. 65, 579-584 (2000)
21. B. S. Katzenellenbogen, M. M. Montano, T. R. Ediger, J. Sun, K. Ekena, G. Lazennec, P. G. Martini, E. M. McInerney, R. age-Mourroux, K. Weis, and J. A. Katzenellenbogen: Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog.Horm Res. 55:163-93; 194-5., 163-193 (2000)
22. C. L. Smith, Z. Nawaz, and B. W. O'Malley: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4- hydroxytamoxifen. Mol Endocrinol. 11, 657-666 (1997)
23. S. Balasenthil, C. J. Barnes, S. K. Rayala, and R. Kumar: Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett. 567, 243-247 (2004)
24. S. K. Rayala, A. H. Talukder, S. Balasenthil, R. Tharakan, C. J. Barnes, R. A. Wang, C. M. Aldaz, S. Khan, and R. Kumar: P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res. 66, 1694-1701 (2006)
25. W. Zwart, A. Griekspoor, V. Berno, K. Lakeman, K. Jalink, M. Mancini, J. Neefjes, and R. Michalides: PKAinduced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J. 26, 3534-3544 (2007)
26. S. Kato, H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, and H. Kawashima: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-1494 (1995)
27. S. Ali and R. C. Coombes: Endocrine-responsive breast cancer and strategies for combating resistance. Nat.Rev.Cancer. 2, 101-112 (2002)
28. R. A. Campbell, P. Bhat-Nakshatri, N. M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 276, 9817-9824 (2001)
29. Z. Wang, X. Zhang, P. Shen, B. W. Loggie, Y. Chang, and T. F. Deuel: A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogendependent membrane-initiated mitogenic signaling. Proc.Natl Acad.Sci U.S.A. 103, 9063-9068 (2006)
30. G. A. Figtree, D. McDonald, H. Watkins, and K. M. Channon: Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation. 107, 120- 126 (2003)
31. L. Li, M. P. Haynes, and J. R. Bender: Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc.Natl Acad.Sci U.S.A. 100, 4807-4812 (2003)
32. M. Razandi, P. Oh, A. Pedram, J. Schnitzer, and E. R. Levin: ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol. 16, 100-115 (2002)
33. A. Pedram, M. Razandi, R. C. Sainson, J. K. Kim, C. C. Hughes, and E. R. Levin: A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem. 282, 22278-22288 (2007)
34. D. C. Marquez, H. W. Chen, E. M. Curran, W. V. Welshons, and R. J. Pietras: Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol. 246, 91-100 (2006)
35. Q. Lu, D. C. Pallas, H. K. Surks, W. E. Baur, M. E. Mendelsohn, and R. H. Karas: Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc.Natl Acad.Sci U.S.A. 101, 17126-17131 (2004)
36. R. X. Song, C. J. Barnes, Z. Zhang, Y. Bao, R. Kumar, and R. J. Santen: The role of Shc and insulinlike growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc.Natl.Acad.Sci.USA 101, 2076-2081 (2004)
37. D. C. Marquez, J. Lee, T. Lin, and R. J. Pietras: Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine. 16, 73-81 (2001)
38. D. C. Marquez and R. J. Pietras: Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 20, 5420-5430 (2001)
39. R. J. Pietras, J. Arboleda, D. M. Reese, N. Wongvipat, M. D. Pegram, L. Ramos, C. M. Gorman, M. G. Parker, M. X. Sliwkowski, and D. J. Slamon: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormoneindependent growth in human breast cancer cells. Oncogene. 10, 2435-2446 (1995)
40. M. Razandi, A. Pedram, I. Merchenthaler, G. L. Greene, and E. R. Levin: Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol. 18, 2854-2865 (2004)
41. M. Razandi, A. Pedram, E. M. Rosen, and E. R. Levin: BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol. 24, 5900-5913 (2004)
42. A. Pedram, M. Razandi, M. Aitkenhead, C. C. Hughes, and E. R. Levin: Integration of the nongenomic and genomic actions of estrogen. Membraneinitiated signaling by steroid to transcription and cell biology. J Biol Chem. 277, 50768-50775 (2002)
43. M. Razandi, A. Pedram, and E. R. Levin: Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol. 14, 1434-1447 (2000)
44. M. Razandi, A. Pedram, G. L. Greene, and E. R. Levin: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol. 13, 307-319 (1999)
45. A. Pedram, M. Razandi, and E. R. Levin: Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 20, 1996-2009 (2006)
46. A. V. Lee, B. L. Guler, X. Sun, S. Oesterreich, Q. P. Zhang, E. M. Curran, and W. V. Welshons: Oestrogen receptor is a critical component required for insulin-like growth factor (IGF)-mediated signalling and growth in MCF-7 cells. Eur J Cancer. 36 Suppl 4:109-10., 109-110 (2000)
47. A. Pedram, M. Razandi, J. Kehrl, and E. R. Levin: Natriuretic peptides inhibit G protein activation. Mediation through cross-talk between cyclic GMP-dependent protein kinase and regulators of G protein-signaling proteins. J Biol Chem. 275, 7365-7372 (2000)
48. M. Razandi, A. Pedram, S. T. Park, and E. R. Levin: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem. 278, 2701-2712 (2003)
49. M. Razandi, G. Alton, A. Pedram, S. Ghonshani, P. Webb, and E. R. Levin: Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol. 23, 1633-1646 (2003)
50. R. Schiff, S. A. Massarweh, J. Shou, L. Bharwani, S. K. Mohsin, and C. K. Osborne: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 10, 331S- 336S (2004)
51. M. B. Martin, T. F. Franke, G. E. Stoica, P. Chambon, B. S. Katzenellenbogen, B. A. Stoica, M. S. McLemore, S. E. Olivo, and A. Stoica: A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulinlike growth factor I. Endocrinology. 141, 4503-4511 (2000)
52. R. C. Wu, J. Qin, Y. Hashimoto, J. Wong, J. Xu, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley: Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. Mol Cell Biol. 22, 3549-3561 (2002)
53. J. Font de Mora and M. Brown: AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 20, 5041-5047 (2000)
54. R. C. Wu, J. Qin, P. Yi, J. Wong, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley: Selective phosphorylations of the SRC- 3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell. 15, 937-949 (2004)
55. C. K. Osborne, V. Bardou, T. A. Hopp, G. C. Chamness, S. G. Hilsenbeck, S. A. Fuqua, J. Wong, D. C. Allred, G. M. Clark, and R. Schiff: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J.Natl.Cancer I. 95, 353-361 (2003)
56. T. Kirkegaard, L. M. McGlynn, F. M. Campbell, S. Muller, S. M. Tovey, B. Dunne, K. V. Nielsen, T. G. Cooke, and J. M. Bartlett: Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res. 13, 1405-1411 (2007)
57. J. Shou, S. Massarweh, C. K. Osborne, A. E. Wakeling, S. Ali, H. Weiss, and R. Schiff: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu crosstalk in ER/HER2-positive breast cancer. J.Natl.Cancer Inst. 96, 926-935 (2004)
58. M. C. Gutierrez, S. Detre, S. Johnston, S. K. Mohsin, J. Shou, D. C. Allred, R. Schiff, C. K. Osborne, and M. Dowsett: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 23, 2469-2476 (2005)
59. S. Meng, D. Tripathy, S. Shete, R. Ashfaq, B. Haley, S. Perkins, P. Beitsch, A. Khan, D. Euhus, C. Osborne, E. Frenkel, S. Hoover, M. Leitch, E. Clifford, E. Vitetta, L. Morrison, D. Herlyn, L. W. Terstappen, T. Fleming, T. Fehm, T. Tucker, N. Lane, J. Wang, and J. Uhr: HER-2 gene amplification can be acquired as breast cancer progresses. Proc.Natl.Acad.Sci U.S.A 101, 9393-9398 (2004)
60. R. I. Nicholson, C. Staka, F. Boyns, I. R. Hutcheson, and J. M. Gee: Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr.Relat.Cancer 11, 623-641 (2004)
61. N. J. Jordan, J. M. Gee, D. Barrow, A. E. Wakeling, and R. I. Nicholson: Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat. 87, 167-180 (2004)
62. J. M. Knowlden, I. R. Hutcheson, H. E. Jones, T. Madden, J. M. Gee, M. E. Harper, D. Barrow, A. E. Wakeling, and R. I. Nicholson: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 144, 1032-1044 (2003)
63. J. M. Gee, M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling, and R. I. Nicholson: The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology. 144, 5105-5117 (2003)
64. J. M. Knowlden, I. R. Hutcheson, D. Barrow, J. M. Gee, and R. I. Nicholson: Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology. 146, 4609-4618 (2005)
65. S. Soni, B. T. Lin, A. August, R. I. Nicholson, and K. H. Kirsch: Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3- kinase/Akt survival pathway in tamoxifen resistant breast cancer cells. J Cell Biochem. 107, 364-375 (2009)
66. H. Kurokawa, A. E. Lenferink, J. F. Simpson, P. I. Pisacane, M. X. Sliwkowski, J. T. Forbes, and C. L. Arteaga: Inhibition of HER2/neu (erbB-2) and mitogenactivated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60, 5887-5894 (2000)
67. A. S. Clark, K. West, S. Streicher, and P. A. Dennis: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol.Cancer Ther. 1, 707-717 (2002)
68. L. A. deGraffenried, W. E. Friedrichs, D. H. Russell, E. J. Donzis, A. K. Middleton, J. M. Silva, R. A. Roth, and M. Hidalgo: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin.Cancer Res. 10, 8059-8067 (2004)
69. A. Boulay, J. Rudloff, J. Ye, S. Zumstein-Mecker, T. O'Reilly, D. B. Evans, S. Chen, and H. A. Lane: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 11, 5319-5328 (2005)
70. Y. Zhou, C. Yau, J. W. Gray, K. Chew, S. H. Dairkee, D. H. Moore, U. Eppenberger, S. Eppenberger-Castori, and C. C. Benz: Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer. 7:59., 59 (2007)
71. R. B. Riggins, A. Zwart, R. Nehra, and R. Clarke: The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther. 4, 33-41 (2005)
72. M. De Laurentiis, G. Arpino, E. Massarelli, A. Ruggiero, C. Carlomagno, F. Ciardiello, G. Tortora, D. D'Agostino, F. Caputo, G. Cancello, E. Montagna, L. Malorni, L. Zinno, R. Lauria, A. R. Bianco, and P. S. De: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin.Cancer Res. 11, 4741-4748 (2005)
73. R. I. Nicholson, R. A. McClelland, P. Finlay, C. L. Eaton, W. J. Gullick, A. R. Dixon, J. F. Robertson, I. O. Ellis, and R. W. Blamey: Relationship between EGF-R, cerbB- 2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer. 29A, 1018-1023 (1993)
74. S. G. Archer, A. Eliopoulos, D. Spandidos, D. Barnes, I. O. Ellis, R. W. Blamey, R. I. Nicholson, and J. F. Robertson: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br.J Cancer. 72, 1259-1266 (1995)
75. G. Arpino, S. J. Green, D. C. Allred, D. Lew, S. Martino, C. K. Osborne, and R. M. Elledge: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 10, 5670-5676 (2004)
76. S. Tovey, B. Dunne, C. J. Witton, A. Forsyth, T. G. Cooke, and J. M. Bartlett: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res. 11, 4835-4842 (2005)
77. J. M. Giltnane, L. Ryden, M. Cregger, P. O. Bendahl, K. Jirstrom, and D. L. Rimm: Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol. 25, 3007-3014 (2007)
78. M. J. Ellis, A. Coop, B. Singh, L. Mauriac, A. Llombert- Cussac, F. Janicke, W. R. Miller, D. B. Evans, M. Dugan, C. Brady, E. Quebe-Fehling, and M. Borgs: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19, 3808-3816 (2001)
79. I. E. Smith, M. Dowsett, S. R. Ebbs, J. M. Dixon, A. Skene, J. U. Blohmer, S. E. Ashley, S. Francis, I. Boeddinghaus, and G. Walsh: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J.Clin.Oncol. 23, 5108-5116 (2005)
80. W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price: Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin.Chem. 49, 1579-1598 (2003)
81. A. Lipton, K. Leitzel, S. M. Ali, L. Demers, H. A. Harvey, H. A. Chaudri-Ross, D. Evans, R. Lang, W. Hackl, P. Hamer, and W. Carney: Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer. 104, 257-263 (2005)
82. G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, P. S. De, C. K. Osborne, and R. Schiff: Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 99, 694-705 (2007)
83. A. Argiris, C. X. Wang, S. G. Whalen, and M. P. DiGiovanna: Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res. 10, 1409- 1420 (2004)
84. I. Chu, K. Blackwell, S. Chen, and J. Slingerland: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferationand estrogen-dependent gene expression in antiestrogenresistant breast cancer. Cancer Res. 65, 18-25 (2005)
85. W. Xia, S. Bacus, P. Hegde, I. Husain, J. Strum, L. Liu, G. Paulazzo, L. Lyass, P. Trusk, J. Hill, J. Harris, and N. L. Spector: A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc.Natl Acad.Sci U.S.A. 103, 7795-7800 (2006)
86. S. Massarweh, C. K. Osborne, S. Jiang, A. E. Wakeling, M. Rimawi, S. K. Mohsin, S. Hilsenbeck, and R. Schiff: Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 66, 8266-8273 (2006)
87. P. K. Marcom, C. Isaacs, L. Harris, Z. W. Wong, A. Kommarreddy, N. Novielli, G. Mann, Y. Tao, and M. J. Ellis: The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 102, 43- 49 (2007)
88. J. R. Mackey, B. Kaufman, M. Clemens, P. P. Bapsy, A. Vaid, A. Wardley, S. Tjulandin, M. Jahn, M. Lehle, and A Jones: Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic brest cancer. Breast Cancer Res.Treat. 100, S5 (2006)
89. Neoadjuvant anastrozole alone or with gefitinib in early breast cancer: a phase II placebo-controlled trial (study 223) with biological and clinical outcomes. J.Clin.Oncol. Suppl 18, 515 (2010)
90. A. Polychronis, H. D. Sinnett, D. Hadjiminas, H. Singhal, J. L. Mansi, D. Shivapatham, S. Shousha, J. Jiang, D. Peston, N. Barrett, D. Vigushin, K. Morrison, E. Beresford, S. Ali, M. J. Slade, and R. C. Coombes: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 6, 383-391 (2005)
91. A. Buzdar, J. Douma, N. Davidson, R. Elledge, M. Morgan, R. Smith, L. Porter, J. Nabholtz, X. Xiang, and C. Brady: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 19, 3357-3366 (2001)
92. M. Kaufmann, E. Bajetta, L. Y. Dirix, L. E. Fein, S. E. Jones, N. Zilembo, J. L. Dugardyn, C. Nasurdi, R. G. Mennel, J. Cervek, C. Fowst, A. Polli, S. E. di, A. Arkhipov, G. Piscitelli, L. L. Miller, and G. Massimini: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 18, 1399-1411 (2000)
93. H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez- Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H. P. Sleeboom, F. Jaenicke, A. Pluzanska, M. Dank, D. Becquart, P. P. Bapsy, E. Salminen, R. Snyder, H. Chaudri- Ross, R. Lang, P. Wyld, and A. Bhatnagar: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 21, 2101- 2109 (2003)
94. H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez- Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H. P. Sleeboom, F. Janicke, A. Pluzanska, M. Dank, D. Becquart, P. P. Bapsy, E. Salminen, R. Snyder, M. Lassus, J. A. Verbeek, B. Staffler, H. A. Chaudri-Ross, and M. Dugan: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 19, 2596-2606 (2001)
95. J. Bonneterre, A. Buzdar, J. M. Nabholtz, J. F. Robertson, B. Thurlimann, E. M. von, T. Sahmoud, A. Webster, and M. Steinberg: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 92, 2247- 2258 (2001)
96. A. Milla-Santos, L. Milla, J. Portella, L. Rallo, M. Pons, E. Rodes, J. Casanovas, and M. Puig-Gali: Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am.J Clin Oncol. 26, 317-322 (2003)
97. J. M. Nabholtz, J. Bonneterre, A. Buzdar, J. F. Robertson, and B. Thurlimann: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer. 39, 1684-1689 (2003)
98. J. M. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, and E. M. von: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 18, 3758-3767 (2000)
99. R. Paridaens, L. Dirix, C. Lohrisch, L. Beex, M. Nooij, D. Cameron, L. Biganzoli, T. Cufer, L. Duchateau, A. Hamilton, J. P. Lobelle, and M. Piccart: Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann.Oncol. 14, 1391-1398 (2003)
100. I. E. Smith and M. Dowsett: Aromatase inhibitors in breast cancer. N.Engl.J.Med. 348, 2431-2442 (2003)
101. J. F. Forbes, J. Cuzick, A. Buzdar, A. Howell, J. S. Tobias, and M. Baum: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100- month analysis of the ATAC trial. Lancet Oncol. 9, 45-53 (2008)
102. A. S. Coates, A. Keshaviah, B. Thurlimann, H. Mouridsen, L. Mauriac, J. F. Forbes, R. Paridaens, M. Castiglione-Gertsch, R. D. Gelber, M. Colleoni, I. Lang, M. L. Del, I. Smith, J. Chirgwin, J. M. Nogaret, T. Pienkowski, A. Wardley, E. H. Jakobsen, K. N. Price, and A. Goldhirsch: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 25, 486-492 (2007)
103. R. Jakesz, W. Jonat, M. Gnant, M. Mittlboeck, R. Greil, C. Tausch, J. Hilfrich, W. Kwasny, C. Menzel, H. Samonigg, M. Seifert, G. Gademann, M. Kaufmann, and J. Wolfgang: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 366, 455-462 (2005)
104. F. Boccardo, A. Rubagotti, P. Guglielmini, A. Fini, G. Paladini, M. Mesiti, M. Rinaldini, S. Scali, M. Porpiglia, C. Benedetto, N. Restuccia, F. Buzzi, R. Franchi, B. Massidda, V. Distante, D. Amadori, and P. Sismondi: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann.Oncol. 17 Suppl 7:vii10-4., vii10-vii14 (2006)
105. R. C. Coombes, L. S. Kilburn, C. F. Snowdon, R. Paridaens, R. E. Coleman, S. E. Jones, J. Jassem, d. van, V, T. Delozier, I. Alvarez, M. L. Del, O. Ortmann, K. Diedrich, A. S. Coates, E. Bajetta, S. B. Holmberg, D. Dodwell, E. Mickiewicz, J. Andersen, P. E. Lonning, G. Cocconi, J. Forbes, M. Castiglione, N. Stuart, A. Stewart, L. J. Fallowfield, G. Bertelli, E. Hall, R. G. Bogle, M. Carpentieri, E. Colajori, M. Subar, E. Ireland, and J. M. Bliss: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 369, 559-570 (2007)
106. M. Dowsett, J. Cuzick, J. Ingle, A. Coates, J. Forbes, J. Bliss, M. Buyse, M. Baum, A. Buzdar, M. Colleoni, C. Coombes, C. Snowdon, M. Gnant, R. Jakesz, M. Kaufmann, F. Boccardo, J. Godwin, C. Davies, and R. Peto: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol.28, 509-518 (2010)
107. L. A. Martin, I. Farmer, S. R. Johnston, S. Ali, and M. Dowsett: Elevated ERK1/ERK2/estrogen receptor crosstalk enhances estrogen-mediated signaling during longterm estrogen deprivation. Endocr.Relat Cancer. 12 Suppl 1:S75-84., S75-S84 (2005)
108. G. J. Sabnis, D. Jelovac, B. Long, and A. Brodie: The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res. 65, 3903-3910 (2005)
109. R. J. Santen, R. X. Song, Z. Zhang, R. Kumar, M. H. Jeng, S. Masamura, J. Lawrence, Jr., L. P. MacMahon, W. Yue, and L. Berstein: Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J.Steroid Biochem.Mol.Biol. 95, 155-165 (2005)
110. D. Jelovac, G. Sabnis, B. J. Long, L. Macedo, O. G. Goloubeva, and A. M. Brodie: Activation of mitogenactivated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 65, 5380-5389 (2005)
111. A. Brodie, D. Jelovac, G. Sabnis, B. Long, L. Macedo, and O. Goloubeva: Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem.Mol Biol. 95, 41-48 (2005)
112. M. Mello-Grand V. Singh, C. Ghimenti, M. Scatolini, L. Regolo, E. Grosso, A. Zambelli, G. A. Da Prada, L. Villani, V. Fregoni, P. Baiardi, S. Marsoni, W. R. Miller, A. Costa, and G. Chiorino: Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. Breast Cancer Res Treat.2010)
113. E. Tagliabue, A. Balsari, M. Campiglio, and S. M. Pupa: HER2 as a target for breast cancer therapy. Expert Opin.Biol.Ther. 10, 711-724 (2010)
114. K. De Santes, D. Slamon, S. K. Anderson, M. Shepard, B. Fendly, D. Maneval, and O. Press: Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res. 52, 1916-1923 (1992)
115. P. Carter, L. Presta, C. M. Gorman, J. B. Ridgway, D. Henner, W. L. Wong, A. M. Rowland, C. Kotts, M. E. Carver, and H. M. Shepard: Humanization of an antip185HER2 antibody for human cancer therapy. Proc.Natl.Acad.Sci.USA 89, 4285-4289 (1992)
116. J. Baselga, L. Norton, J. Albanell, Y. M. Kim, and J. Mendelsohn: Recombinant humanized anti-HER2 antibody (Herceptin(TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831 (1998)
117. D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N.Engl.J.Med. 344, 783-792 (2001)
118. S. Ménard, P. Casalini, M. Campiglio, S. M. Pupa, and E. Tagliabue: Role of HER2/neu in tumor progression and therapy. Cell.Mol.Life Sci. 61, 2965-2978 (2004)
119. M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. H. Barrios, G. Steger, C. S. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Lang, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. M. Suter, J. Ruschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. S. Dolci, and R. D. Gelber: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N.Engl.J.Med. 353, 1659- 1672 (2005)
120. E. H. Romond, E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer, Jr., N. E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P. A. Kaufman, S. M. Swain, T. M. Pisansky, L. Fehrenbacher, L. A. Kutteh, V. G. Vogel, D. W. Visscher, G. Yothers, R. B. Jenkins, A. M. Brown, S. R. Dakhil, E. P. Mamounas, W. L. Lingle, P. M. Klein, J. N. Ingle, and N. Wolmark: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N.Engl.J.Med. 353, 1673-1684 (2005)
121. I. Smith, M. Procter, R. D. Gelber, S. Guillaume, A. Feyereislova, M. Dowsett, A. Goldhirsch, M. Untch, G. Mariani, J. Baselga, M. Kaufmann, D. Cameron, R. Bell, J. Bergh, R. Coleman, A. Wardley, N. Harbeck, R. I. Lopez, P. Mallmann, K. Gelmon, N. Wilcken, E. Wist, R. P. Sanchez, and M. J. Piccart-Gebhart: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369, 29-36 (2007)
122. D. Slamon, W. Eiermann, N. Robert, and et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2/neu positive early breast cancer patients (abstract 52). Breast Cancer Res Treat. 100S (2006)
123. H. Joensuu, P. L. Kellokumpu-Lehtinen, P. Bono, T. Alanko, V. Kataja, R. Asola, T. Utriainen, R. Kokko, A. Hemminki, M. Tarkkanen, T. Turpeenniemi-Hujanen, S. Jyrkkio, M. Flander, L. Helle, S. Ingalsuo, K. Johansson, A. S. Jaaskelainen, M. Pajunen, M. Rauhala, J. Kaleva- Kerola, T. Salminen, M. Leinonen, I. Elomaa, and J. Isola: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N.Engl.J.Med. 354, 809-820 (2006)
124. M. Spielmann, H. Roche, Y. Humblet, and et al: 3- year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial (abstract 72). 106S2007)
125. E. A. Perez, E. H. Romond, V. J. Suman, and et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (abstract 512). J.Clin.Oncol. 25S, 2007)
126. E. A. Mittendorf, Y. Wu, M. Scaltriti, F. Meric- Bernstam, K. K. Hunt, S. Dawood, F. J. Esteva, A. U. Buzdar, H. Chen, S. Eksambi, G. N. Hortobagyi, J. Baselga, and A. M. Gonzalez-Angulo: Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 15, 7381-7388 (2009)
127. M. Untch, M. Rezai, S. Loibl, P. A. Fasching, J. Huober, H. Tesch, I. Bauerfeind, J. Hilfrich, H. Eidtmann, B. Gerber, C. Hanusch, T. Kuhn, B. A. du, J. U. Blohmer, C. Thomssen, C. S. Dan, C. Jackisch, M. Kaufmann, K. Mehta, and M. G. von: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol.28, 2024-2031 (2010)
128. L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, S. Tjulandin, M. Zambetti, F. Vazquez, M. Byakhow, M. Lichinitser, M. A. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, A. Bozhok, R. Baronio, A. Feyereislova, C. Barton, P. Valagussa, and J. Baselga: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 375, 377-384 (2010)
129. R. Nahta, T. Takahashi, N. T. Ueno, M. C. Hung, and F. J. Esteva: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 64, 3981-3986 (2004)
130. K. Berns, H. M. Horlings, B. T. Hennessy, M. Madiredjo, E. M. Hijmans, K. Beelen, S. C. Linn, A. M. Gonzalez-Angulo, K. Stemke-Hale, M. Hauptmann, R. L. Beijersbergen, G. B. Mills, d. van, V, and R. Bernards: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 12, 395-402 (2007)
131. T. Fujita, H. Doihara, K. Kawasaki, D. Takabatake, H. Takahashi, K. Washio, K. Tsukuda, Y. Ogasawara, and N. Shimizu: PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2- overexpressing breast cancer. Br.J.Cancer 94, 247-252 (2006)
132. T. Fujita, H. Doihara, K. Washio, K. Kawasaki, D. Takabatake, H. Takahashi, K. Tsukuda, Y. Ogasawara, and N. Shimizu: Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs 17, 455-462 (2006)
133. C. H. Lu, S. L. Wyszomierski, L. M. Tseng, M. H. Sun, K. H. Lan, C. L. Neal, G. B. Mills, G. N. Hortobagyi, F. J. Esteva, and D. Yu: Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin.Cancer Res. 13, 5883- 5888 (2007)
134. Y. Nagata, K. H. Lan, X. Zhou, M. Tan, F. J. Esteva, A. A. Sahin, K. S. Klos, P. Li, B. P. Monia, N. T. Nguyen, G. N. Hortobagyi, M. C. Hung, and D. Yu: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004)
135. A. B. Motoyama, N. E. Hynes, and H. A. Lane: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factorrelated peptides. Cancer Res. 62, 3151-3158 (2002)
136. J. Anido, M. Scaltriti, J. J. Bech Serra, J. B. Santiago, F. R. Todo, J. Baselga, and J. Arribas: Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25, 3234-3244 (2006)
137. M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, C. S. Di, X. Matias-Guiu, S. Cajal, J. Arribas, and J. Baselga: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J.Natl.Cancer I. 99, 628-638 (2007)
138. S Ménard, and on behalf of the Demetra Group: Observational Demetra study: Survival of metastatic breast carcinoma patients after treatment with trastuzumab. J.Clin.Oncol.ASCO Annual Meeting Proceedings 26, Abstract 1062 (2008)
139. G. Von Minckwitz, A. Du bois, M. Schmidt, N. Maass, T. Cufer, F. E. de Jongh, E. Maartense, C. Zielinski, M. Kaufmann, W. Bauer, K. H. Baumann, M. R. Clemens, R. Duerr, C. Uleer, M. Andersson, R. C. Stein, V. Nekljudova, and S. Loibl: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J.Clin.Oncol. 27, 1999- 2006 (2009)
140. G. Cancello, E. Montagna, D. D'Agostino, M. Giuliano, A. Giordano, L. G. Di, M. Plaitano, P. S. De, and M. De Laurentiis: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res. 10, R60 (2008)
141. R. Gennari, S. Ménard, F. Fagnoni, L. Ponchio, M. Scelsi, E. Tagliabue, F. Castiglioni, L. Villani, C. Magalotti, N. Gibelli, B. Oliviero, B. Ballardini, G. Da Prada, A. Zambelli, and A. Costa: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin.Cancer Res. 10, 5650-5655 (2004)
142. S. Varchetta, N. Gibelli, B. Oliviero, E. Nardini, R. Gennari, L. Santo Silva, E. Tagliabue, S. Ménard, A. Costa, and F. Fagnoni: Elements related to heterogeneity of antibody-dependent cell cytotoxicity (ADCC) in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2. Cancer Res. 67, 11991- 11999 (2007)
143. S. Paik, C. Kim, and N. Wolmark: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N.Engl.J.Med. 358, 1409-1411 (2008)
144. A. Magnifico, L. Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, E. Fontanella, S. Ménard, and E. Tagliabue: Tumor-initiating cells of HER2- positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. Clin.Cancer Res. 15, 2010-2021 (2009)
145. H. Korkaya, A. Paulson, F. Iovino, and M. S. Wicha: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene1- 11 (2008)
146. C. L. Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. Stewart, and M. Press: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J.Clin.Oncol. 20, 719-726 (2002)
147. M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J.Clin.Oncol. 17, 2639-2648 (1999)
148. M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, A. Lluch, J. Kennedy, K. O'Byrne, P. Conte, M. Green, C. Ward, K. Mayne, and J. M. Extra: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J.Clin.Oncol. 23, 4265-4274 (2005)
149. G. Mariani, A. Fasolo, B. E. De, and L. Gianni: Trastuzumab as adjuvant systemic therapy for HER2- positive breast cancer. Nat.Clin.Pract.Oncol. 6, 93-104 (2009)
150. E. Bria, F. Cuppone, M. Milella, S. Verma, P. Carlini, C. Nistico, V. Vaccaro, A. Rossi, G. Tonini, F. Cognetti, and E. Terzoli: Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin.Biol Ther. 8, 1963-1971 (2008)
151. H. A. Burris, III, H. I. Hurwitz, E. C. Dees, A. Dowlati, K. L. Blackwell, B. O'Neil, P. K. Marcom, M. J. Ellis, B. Overmoyer, S. F. Jones, J. L. Harris, D. A. Smith, K. M. Koch, A. Stead, S. Mangum, and N. L. Spector: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin.Oncol. 23, 5305-5313 (2005)
152. K. E. Lackey: Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr.Top.Med.Chem. 6, 435-460 (2006)
153. G. E. Konecny, M. D. Pegram, N. Venkatesan, R. Finn, G. Yang, M. Rahmeh, M. Untch, D. W. Rusnak, G. Spehar, R. J. Mullin, B. R. Keith, T. M. Gilmer, M. Berger, K. C. Podratz, and D. J. Slamon: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2- overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630-1639 (2006)
154. C. G. Murphy and M. Fornier: HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston.Park). 24, 410-415 (2010)
155. H. J. Burstein, A. M. Storniolo, S. Franco, J. Forster, S. Stein, S. Rubin, V. M. Salazar, and K. L. Blackwell: A phase II study of lapatinib monotherapy in chemotherapyrefractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann.Oncol. 19, 1068-1074 (2008)
156. K. L. Blackwell, H. Burstein, M. Pegram, and et al: Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J.Clin.Oncol.Suppl. 23, 256s-Abstract 3004 (2005)
157. H. Iwata, M. Toi, Y. Fujiwara, and et al: Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Breast Cancer Symphosium , San Antonio, Texas-Abstract 1091 (2006)
158. H. L. Gomez, D. C. Doval, M. A. Chavez, P. C. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W. Chow, M. C. Arbushites, M. A. Casey, m. S. Berger, S. H. Stein, and G. W. Sledge: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J.Clin.Oncol. 26, 2999-3005 (2008)
159. C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein, and D. Cameron: Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N.Engl.J.Med. 355, 2733- 2743 (2006)
160. J. O'Shaughnessy, K. L. Blackwell, H. Burstein, A. M. Storniolo, G. Sledge, J. Baselga, M. Koehler, S. Laabs, A. Florance, and D. F. Roychowdhury: A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J.Clin.Oncol.ASCO Annual Meeting Proceedings 26, 44S (2008)
161. B. M. Fendly, M. Winget, R. M. Hudziak, M. T. Lipari, M. A. Napier, and A. Ullrich: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50, 1550-1558 (1990)
162. J. Baselga, D. Cameron, D. Miles, and et al: Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J.Clin.Oncol.Suppl. 25, abstract 1004 (2008)
163. M. Beeram, H. A. Burris, S. Modi, M. Birkner, S. Girish, J. Tibbitts, S. N. Holden, S. G. Lutzker, and I. E Krop: A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in pateints (pts) with advanced HER2+ breast cancer (BC). Am.Soc.Clin.Oncol. Annual Meeting, Abstract 1028 (2008)
164. S. N. Hoden, M. Beeram, I. E. Krop, H. A. Burris, M. Birkner, S. Girish, and et al: A phase I study of weekly dosing of trastuzumab-DM1 (T-CM1) in patients (pts) with advanced HER2+ breast cancer (BC). Am.Soc.Clin.Oncol. Annual Meeting, Abstract 1029 (2008)
165. J. Staaf, M. Ringner, J. Vallon-Christersson, G. Jonsson, P. O. Bendahl, K. Holm, A. Arason, H. Gunnarsson, C. Hegardt, B. A. Agnarsson, L. Luts, D. Grabau, M. Ferno, P. O. Malmstrom, O. T. Johannsson, N. Loman, R. B. Barkardottir, and A. Borg: Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol. 28, 1813-1820 (2010)
166. B. Kreike, K. M. van, H. Horlings, B. Weigelt, H. Peterse, H. Bartelink, and d. van, V: Gene expression profiling and histopathological characterization of triplenegative/ basal-like breast carcinomas. Breast Cancer Res. 9, R65 (2007)
167. B. Haupt, J. Y. Ro, and M. R. Schwartz: Basal-like breast carcinoma: a phenotypically distinct entity. Arch.Pathol Lab Med. 134, 130-133 (2010)
168. J. S. Reis-Filho and A. N. Tutt: Triple negative tumours: a critical review. Histopathology. 52, 108-118 (2008)
169. B. P. Schneider, E. P. Winer, W. D. Foulkes, J. Garber, C. M. Perou, A. Richardson, G. W. Sledge, and L. A. Carey: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 14, 8010-8018 (2008)
170. D. F. Hayes, A. D. Thor, L. G. Dressler, D. Weaver, S. Edgerton, D. Cowan, G. Broadwater, L. J. Goldstein, S. Martino, J. N. Ingle, I. C. Henderson, L. Norton, E. P. Winer, C. A. Hudis, M. J. Ellis, and D. A. Berry: HER2 and response to paclitaxel in node-positive breast cancer. N.Engl.J Med. 357, 1496-1506 (2007)
171. O. Gluz, U. A. Nitz, N. Harbeck, E. Ting, R. Kates, A. Herr, W. Lindemann, C. Jackisch, W. E. Berdel, H. Kirchner, B. Metzner, F. Werner, G. Schutt, M. Frick, C. Poremba, R. allo-Danebrock, and S. Mohrmann: Triplenegative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann.Oncol. 19, 861-870 (2008)
172. C. R. James, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin: BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist. 12, 142-150 (2007)
173. B. Klencke, Bhattacharya, S., Samant, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Davidson, N. E., and Miller, K. Independent review of E2100 validates progression-free survival (PFS) improvement with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC). J.Clin.Oncol. 26, 50s (2008)
174. D. W. Miller, A. Chan, G. Romieu, L. Y. Dirix, J. Cortes, X. Pivot, P. Tomczak, T. Taran, N. Harbeck, and G. G. Steger: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with dodetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J.Clin.Oncol. 26, 1008s (2008)
175. H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, C. M. Baum, and K. D. Miller: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J.Clin.Oncol. 26, 1810-1816 (2008)
176. L. Carey, H. Rugo, and P. Marcom: TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J.Clin.Oncol. 26, 2008)
177. C. R. Calabrese, R. Almassy, S. Barton, M. A. Batey, A. H. Calvert, S. Canan-Koch, B. W. Durkacz, Z. Hostomsky, R. A. Kumpf, S. Kyle, J. Li, K. Maegley, D. R. Newell, E. Notarianni, I. J. Stratford, D. Skalitzky, H. D. Thomas, L. Z. Wang, S. E. Webber, K. J. Williams, and N. J. Curtin: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 96, 56-67 (2004)
178. P. A. Nguewa, M. A. Fuertes, V. Cepeda, C. Alonso, C. Quevedo, M. Soto, and J. M. Perez: Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatinresistant tumor cells. Med.Chem. 2, 47-53 (2006)
179. N. Turner, M. B. Lambros, H. M. Horlings, A. Pearson, R. Sharpe, R. Natrajan, F. C. Geyer, K. M. van, B. Kreike, A. Mackay, A. Ashworth, d. van, V, and J. S. Reis- Filho: Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 29, 2013-2023 (2010)